1	Associations between genetically predicted iron status and cardiovascular disease risk: A
2	Mendelian randomization study
3	
4	Alexa Barad, MS, RD <sup>1</sup> , Andrew G. Clark, PhD <sup>2,3</sup> , Kimberly O. O'Brien, PhD <sup>1</sup> , Eva K.
5	Pressman, MD <sup>4</sup>
6	
7	Affiliations:
8	<sup>1</sup> Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA
9	<sup>2</sup> Department of Molecular Biology and Genetics, Cornell University, Ithaca, New York, USA
10	<sup>3</sup> Department of Computational Biology, Cornell University, Ithaca, New York, USA
11	<sup>4</sup> Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester,
12	New York, USA
13	Short title: Iron status and cardiovascular disease risk
14	Corresponding author: Alexa Barad, Division of Nutritional Sciences, Cornell University, 210
15	Savage Hall, Ithaca, NY, 14850, <u>ab2929@cornell.edu</u> .
16	Word count: 5955
17	
18	
19	
20	
21	

1

### 22 Abstract

Background: Mendelian randomization (MR) studies suggest a causal effect of iron (Fe) status
on cardiovascular disease (CVD) risk, but it is unknown if these associations are confounded by
pleiotropic effects of the instrumental variables (IV) on CVD risk factors. We aimed to investigate
the effect of Fe status on CVD risk controlling for CVD risk factors.

27 Methods: Fe biomarker IVs (total Fe binding capacity (TIBC, *n*=208,422), transferrin saturation

28 (TSAT, *n*=198,516), serum Fe (SI, *n*=236,612), ferritin (*n*=257,953)) were selected from a

29 European GWAS meta-analysis. We performed two-sample univariate (UV) MR of each Fe trait

30 on CVD outcomes (all-cause ischemic stroke (IS), cardioembolic IS (CES), large artery IS (LAS),

31 small vessel IS (SVS), and coronary heart disease (CHD)) from MEGASTROKE (*n*=440,328) and

32 CARDIoGRAMplusC4D (*n*=183,305). We then implemented multivariate (MV) MR conditioning

on six CVD risk factors from independent European samples to evaluate their potential
 confounding and/or mediating effects on the observed Fe-CVD associations.

35 Results: With UVMR analyses, we found higher genetically predicted Fe status to be associated 36 with a greater risk of CES (TSAT: OR 1.17 [95%CI 1.03, 1.33], SI: OR 1.21 [95%CI 1.02, 1.44]; 37 TIBC: OR 0.81 [95%CI 0.69, 0.94]). The detrimental effects of Fe status on CES risk remained 38 unaffected when adjusting for CVD risk factors (all P < 0.05). Additionally, we found diastolic 39 blood pressure (DBP) to mediate between 7.1-8.8% of the total effect of Fe status on CES 40 incidence. While UVMR initially suggested a protective effect of Fe status on LAS and CHD, 41 MVMR analyses factoring CVD risk factors revealed a complete annulment of this perceived 42 protective effect (all P>0.05).

2

43 Discussion: Higher Fe status was associated with a greater risk of CES independent of CVD risk
44 factors, and this effect was partly mediated by DBP. These findings support a role of Fe status as
45 a modifiable risk factor for CES.

46

47 Key words: Mendelian randomization, iron status, ischemic stroke, cardioembolic stroke risk

48 Abbreviations: AF, atrial fibrillation; Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI,

49 body mass index; CARDIoGRAMplusC4D, Coronary ARtery DIsease Genome wide Replication

50 and Meta-analysis plus The Coronary Artery Disease Genetics; CES, cardioembolic ischemic

51 stroke; CHD, coronary heart disease; CVD, cardiovascular disease; DBDS, Danish Blood Donor

52 Study; DBP, diastolic blood pressure;; Fe, iron; HDL, high density lipoprotein cholesterol; HUNT,

53 Trøndelag Health Study; IL-6, interleukin-6; IS, all-cause ischemic stroke; IV, instrumental

54 variable; IVW, inverse variance weighted; LAS, large artery atherosclerosis ischemic stroke; LDL,

55 low density lipoprotein cholesterol; MGI, Michigan Genomics Initiative; MR, Mendelian

56 randomization; MR-PRESSO, Mendelian randomization pleiotropy residual sum and outlier test;

57 MVMR, multivariate Mendelian randomization; NTBI, non-transferrin bound iron; SBP, systolic

58 blood pressure; SVS, small vessel ischemic stroke; TC, total cholesterol; TG, triglycerides; TIBC,

59 total iron binding capacity; TSAT, transferrin saturation; UKBB, UK Biobank.

60

61

- 62
- 63

64

3

# 65 Introduction

66 Iron (Fe) is an essential nutrient needed to support many biological processes. Both 67 extremes of Fe status have been associated with adverse cardiovascular outcomes. Iron deficiency 68 is the most prevalent micronutrient deficiency worldwide and is associated with significant 69 comorbidities affecting 70% of patients with heart failure (1), whereas Fe overload is implicated 70 in numerous cardiometabolic diseases (2). When circulating Fe exceeds the transport carrying 71 capacity of transferrin, Fe begins to circulate free, generating a toxic Fe species known as non-72 transferrin bound Fe (NTBI). Cardiac, pancreatic, and hepatic cells all internalize NTBI via 73 different mechanisms (3, 4). Cellular uptake of NTBI increases the intracellular labile Fe pool 74 resulting in generation of reactive oxygen species and subsequent oxidative tissue damage (5). 75 Excess Fe in cardiomyocytes has been shown to induce ferroptosis, a form of regulated cell death 76 driven by Fe-dependent lipid peroxidation that is linked to cardiovascular disease (CVD) (6).

77 Although a link between Fe overload and CVD risk was proposed over 40 years ago (7), 78 epidemiological data to date have shown conflicting results. Clinical studies have reported 79 associations between atherosclerosis and increased serum Fe (8) or serum ferritin (9-13) 80 concentrations. Consistent with these observations, some studies demonstrated an association 81 between Fe depletion, either by Fe chelation therapy (14) or blood donation (15-17), and a 82 decreased risk of CVD. Conversely, other cross-sectional (18, 19) and longitudinal (20) studies 83 have reported a lack of an association. Most studies evaluating these relationships to date have 84 been conducted in populations with a relatively high prevalence of chronic diseases. As a result, it 85 remains uncertain if the observed variability in Fe status contributes to the onset of these diseases 86 or is a consequence of the diseases themselves, particularly since many commonly used Fe status 87 biomarkers (e.g., ferritin) can be elevated in response to inflammation.

4

88 Mendelian randomization (MR) is a statistical tool that uses genetic variation to explore 89 causal effects of a risk factor on a health outcome in the presence of unknown confounders under 90 three key assumptions: the genetic instruments selected as instrumental variables (IVs) must 1) 91 reliably predict the exposure, 2) only be associated with the outcome through its association with 92 the exposure, and 3) not be associated with confounders of the exposure-outcome association 93 (Figure S1). To date, few MR studies evaluating the effects of Fe status on CVD risk have been 94 published and these have found higher genetically predicted Fe status to be associated with a 95 decreased risk of atherosclerotic disease (21-23) and hypercholesteremia (24) and an increased 96 risk of ischemic stroke (IS) (25) and venous thromboembolism (VTE) (22). These MR studies 97 used three genetic variants in Fe-regulatory genes as IVs selected from a European genome-wide 98 association study (GWAS) of Fe biomarkers in < 50,000 individuals (26). However, the latest 99 GWAS of Fe status biomarkers has reached a sample size of up to 257,953 and increased the 100 number of genome-wide significant loci from 11 to 123 (27). Additionally, the IVs used in 101 published studies do not satisfy all MR assumptions as these have been reported to have genome-102 wide significant associations with known confounders, including cholesterol, blood pressure, and 103 body mass index (BMI). Consequently, it is unknown if the reported associations are confounded 104 by pleiotropic effects of the IVs on CVD risk factors.

In depth analyses using the recently discovered genome-wide significant loci of Fe status as IVs are needed to obtain reliable effect estimates of Fe status on CVD risk. Our aim was to investigate the associations between genetically predicted Fe status and risk of ischemic stroke (IS) and coronary heart disease (CHD) by employing an MR framework that controls for CVD risk factors. A secondary aim was to investigate the pathways by which Fe status influences CVD risk utilizing mediation analyses.

5

### 111 Methods

The work presented was performed using publicly available summary-level data from published GWAS. All analyses were conducted using R version 4.2.2 (The R Foundation for Statistical Computing). Results are reported per STROBE-MR recommendations (**Table S1**).

#### 115 Exposure data source

116 Summary-level data were obtained from the largest Fe GWAS available to date, which 117 consisted of a meta-analysis of GWAS of six European populations (DeCODE, INTERNAL, 118 SardiNIA, Danish Blood Donor Study (DBDS), Trøndelag Health Study (HUNT), and Michigan 119 Genomics Initiative (MGI), for four Fe status biomarkers (serum Fe (SI), transferrin saturation 120 (TSAT), serum ferritin (SF), and total Fe binding capacity (TIBC)) (27) (Table 1). Descriptive 121 characteristics of the populations studied, the biomarker quantification methods utilized, and the 122 data sources are outlined in Table S2. The physiological significance of the Fe status indicators is 123 described in Table S3.

124

#### 125 **Outcome data sources**

126 Detailed information on the outcome data sources used in this study are shown in Table 1127 and Table S4.

128

#### 129 Cardiovascular disease risk factors

130 Known CVD risk factors were selected to 1) investigate the causal effect of Fe on the risk
131 factor using two-sample univariate MR and 2) to investigate the confounding and/or mediating

6

132 effects of the significant risk factors on the associations of genetically predicted Fe status and CVD 133 using multivariate MR (MVMR). The risk factors selected were blood lipids (high density 134 lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), total cholesterol (TC), 135 triglycerides (TG), apolipoprotein A (Apo-A), apolipoprotein B (Apo-B), blood pressure 136 (diastolic blood pressure (DBP) and systolic blood pressure (SBP)), body mass index (BMI), and 137 an inflammatory marker (interleukin-6 (IL-6)). Summary statistics for blood lipids, blood pressure 138 outcomes and BMI were obtained from the UK Biobank and GWAS data for IL-6 were from a 139 meta-analysis of eleven independent European cohorts (28).

#### 140 Cardiovascular diseases

141 CHD, all-cause IS, and IS subtypes were selected as primary CVD outcomes. CHD 142 summary statistics data were obtained from the CARDIoGRAMplusC4D (Coronary ARtery 143 DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery 144 Disease (C4D) Genetics) 1000-Genomes GWAS meta-analysis (29), which consisted of a GWAS 145 meta-analysis of CHD in forty-eight multi-ethnic populations. Of the total sample size, 76% of the 146 participants included were of European descent. Summary-level data for IS and IS subtypes 147 (cardioembolic (CES), large artery atherosclerosis (LAS), small-vessel (SVS)) were obtained from 148 a GWAS meta-analysis in seventeen European populations led by the MEGASTROKE consortium 149 (30). We were unable to rule out potential sample overlap between the MEGASTROKE and the 150 exposure data because both GWAS meta-analyses involved individuals from deCODE. To 151 mitigate the risk of type I error (31), we tested an additional outcome closely related to IS, atrial 152 fibrillation (AF), to validate our findings. Summary-level GWAS data for AF were obtained from 153 a GWAS meta-analysis of European consortiums including Atrial Fibrillation Genetics consortium 154 (AFGen) and the Broad AF study (32).

7

#### 155 Instrumental variable selection

Independent SNPs ( $r^2 < 0.001$ ) associated with each Fe trait at genome-wide significance 156 157 level ( $P < 5x10^{-8}$ ) were extracted from the Fe GWAS meta-analysis (27). Rare SNPs with a minor 158 allele frequency (MAF) < 1% in Europeans were excluded. SNPs defined as being ambiguous with 159 intermediate allele frequencies were removed. Additionally, to further minimize the potential for 160 pleiotropy, SNPs that had direction of effects that were not consistent with systemic Fe status were 161 removed (i.e., higher Fe status results in increased TSAT, serum Fe and ferritin, and decreased 162 TIBC). Lastly, SNPs that were not genotyped in the outcome dataset were replaced by proxy SNPs 163 if available or removed if no proxy SNP was found. Proxy SNPs were defined as a SNP in linkage 164 disequilibrium (LD;  $r^2 > 0.8$ ) with the genetic instrument in a European reference population 165 (Table S5).

166 The strength and validity of the genetic instruments were evaluated by calculating the 167 variance in the Fe trait explained by a SNP ( $R^2$ ) and the F-statistic. The  $R^2$  for each SNP was calculated using the equation  $R^2 = 2\beta^2 \text{ MAF}$  (1-MAF), where  $\beta$  is the regression coefficient from 168 169 the SNP-Fe trait association from the GWAS, and MAF is the minor allele frequency for that SNP. The *F*-statistic was calculated using the equation *F*-statistic =  $(n-k-1/k)(R^2_{\text{instrument}} / 1 - R^2_{\text{instrument}})$ , 170 171 where *n* is the population sample size, *k* is the number of SNPs in the instrument, and  $R^{2}_{instrument}$  is 172 the sum of the  $R^2$  for each SNP included in the instrument (33). We considered the MR standard 173 F-statistic > 10 to indicate adequate instrument strength (33). The SNPs selected as instrumental 174 variables and their respective  $R^2$  and F-statistic are shown in **Table S5**. The  $R^2$  instrument and the F-175 statistic of the instruments were calculated after data harmonization for all four Fe biomarkers for 176 each outcome evaluated as shown in Table S6.

8

#### 178 Mendelian randomization

179 We developed a workflow combining variations of the MR method (Figure 1). Initial 180 analyses consisted of univariate MR analyses to identify major CVD risk factors that are 181 influenced by Fe traits (Figure 1; step 1a) and to evaluate the total effect of Fe traits on CVD 182 outcomes (Figure 1; step 1b). Variables meeting the selection criteria were carried over to step 2, 183 which consisted of MVMR analyses to determine the direct effects of Fe traits on CVD outcomes 184 conditioning on major CVD risk factors (Figure 1; step 2). Lastly, CVD risk factors satisfying the 185 selection criteria were carried over to step 3, where these were evaluated as mediators of the Fe 186 trait-CVD associations and the indirect effects of Fe traits on CVD were calculated (Figure 1; step 187 3). The detailed MR models implemented, and the variables tested at each step are presented in 188 Figure S2.

#### 189 Univariate Mendelian randomization

190 We performed three main MR estimations for each exposure-outcome test, which included 191 the inverse variance weighted (IVW) method under multiplicative random effects (34), the MR-192 Egger method, and the weighted median (WM) method. The IVW method requires either all SNPs 193 used as IVs to be valid instruments or that there is balanced horizontal pleiotropy, whereas the 194 MR-Egger and weighted median are more robust to bias introduced by weak IVs; the MR-Egger 195 is less susceptible to bias introduced by horizontal pleiotropy (35) and the weighted median (WM) 196 provides an unbiased estimate if <50% of the SNPs used as IVs present evidence of pleiotropy 197 (36). When significant evidence of pleiotropy was detected (described below under "sensitivity 198 analyses"), the WM and MR-Egger estimates were prioritized for interpretation of results. 199 Univariate MR analyses were performed using the 'TwoSampleMR' R package (37). MR estimates 200 are presented as the  $\beta$  and standard error (SE) per 1-SD unit change in the Fe status biomarker for

9

201 continuous outcomes, and as odds ratio (OR) and 95% CI per 1-SD unit change in the Fe status
202 biomarker for dichotomous outcomes.

203 Multivariate Mendelian randomization

204 MVMR is an extension of the two-sample univariate MR method that can be employed to 205 estimate the effect of an exposure on an outcome while controlling for confounders (38). We 206 performed MVMR on CVD outcomes meeting our prioritization criteria conditioning on one CVD 207 risk factor at a time. MVMR estimates were calculated using the IVW method and all MVMR 208 analyses were performed using the 'MVMR' R packages (39, 40), which extend the typical MR 209 main and sensitivity tests (IVW and Cochran's *O*) to MVMR analyses. The conditional *F*-statistic, 210 which accounts for the association between each SNP with other exposures included in the 211 estimation, was calculated to assess instrument strength.

#### 212 *Mediation analysis*

213 Mediation analyses were conducted to assess the mechanisms by which Fe status 214 influences CVD outcomes. Effect estimates obtained from the univariate MR (total effects of Fe 215 on CVD (Figure 1; step1a) and CVD risk factor (Figure 1; step1b)) and MVMR (direct effects 216 of Fe on CVD conditioning on a CVD risk factor (Figure 1; step 2)) were used to calculate the 217 indirect effects of Fe status on a CVD outcome using the product of coefficients method (41). This 218 method was selected as the outcomes evaluated are considered rare with a prevalence <10% (42). 219 The SE and 95% CI were calculated using the Delta method (43). The percent of effect mediated 220 by a CVD risk factor was calculated as the estimated indirect effect divided by the total effect from 221 univariate MR x 100 (43). Mediation estimates are presented as the log odds ratio, SE and 95% 222 CI.

10

223

#### 224 Sensitivity Analyses

225 Pleiotropy refers to a phenomenon in which a variant has causal effects on more than one 226 phenotype. In the context of MR, significant bias is introduced when there is evidence of pleiotropy 227 within the genetic instruments (i.e., if the MR assumption 3 is not met). We evaluated the presence 228 of directional pleiotropy using the Cochran's Q statistic and the MR-Egger intercept for the 229 univariate MR analyses. Additionally, we performed the MR pleiotropy residual sum and outlier 230 (MR-PRESSO) test using the 'MRPRESSO' package in R, which identifies pleiotropic outliers 231 (44). When outliers were detected, the MR-PRESSO outlier-corrected effect estimates were 232 calculated and presented. For MVMR analyses, heterogeneity was evaluated with the  $Q_A$  statistic. 233 Lastly, we evaluated potential pleiotropic effects of the SNPs used as genetic instruments using 234 the online tools LDtrait (45) and PhenoScanner (46, 47). We searched for Fe-associated SNPs or SNPs in LD ( $r^2 > 0.8$ ) with these SNPs that had genome-wide significant associations ( $P < 5 \times 10^{-1}$ 235 236 <sup>8</sup>) with CVD risk factors (such as blood lipids, BMI, and blood pressure) or with CVD outcomes 237 (such as CHD, IS, and AF) (Table S5). SNPs previously reported to have a genome-wide 238 significant association with a CVD outcome were excluded in sensitivity analyses for MVMR.

239

### 240 **Power Calculations**

Statistical power for binary outcomes (i.e., CVD outcomes) was calculated using the online tool for power calculations for MR (48) and for continuous outcomes (i.e., CVD risk factors) using published methods and R code (49). Based on our strongest instrumental variable with an  $R^2$  of 0.055 at an  $\alpha$ =0.05, our analyses were sufficiently powered (>80%) to detect an odds ratio  $\leq$  0.94

11

245or  $\geq 1.06$  for CHD,  $\leq 0.93$  or  $\geq 1.07$  for IS,  $\leq 0.81$  or  $\geq 1.19$  for CES,  $\leq 0.83$  or  $\geq 1.17$  for LAS,  $\leq$ 2460.85 or  $\geq 1.15$  for SVS, and  $\leq 0.94$  or  $\geq 1.06$  for AF using two-sample MR. Detailed power247calculations for each Fe exposure-outcome combination are shown in Table S7.

248

249 **Results** 

250 Univariate Mendelian randomization

We used common independent SNPs (**Table S5**) explaining 5.5%, 3.9%, 3.2% and 1.5% of the variance in TSAT, TIBC, serum Fe and ferritin, respectively. Instrument *F*-statistic for all four Fe biomarkers ranged from 109 to 1024 after harmonization of exposure and outcome data (**Table S6**).

The MR estimates for the effects of genetically predicted Fe status on CVD risk factors are shown in **Tables S8-S11**. For the Fe-blood lipids, Fe-BP, and Fe-BMI analyses the WM and MR-Egger estimates were prioritized for interpretation of results as the Cochran's Q statistic demonstrated evidence of pleiotropy between genetic instruments (P < 0.05); little to no evidence of pleiotropy was evident from the MR-Egger intercept test (P > 0.05). For the Fe-IL-6 analyses, no evidence of heterogeneity was observed (P > 0.05 for the Cochran's Q statistic and MR-Egger intercept); thus, the IVW MR estimates were taken into consideration.

Higher genetically predicted TSAT, indicative of higher Fe status, was associated with lower LDL cholesterol (WM:  $\beta = -0.11$ ; SE = 0.01,  $P = 3.9 \times 10^{-14}$ ), TC (WM:  $\beta = -0.10$ ; SE = 0.02,  $P = 5.3 \times 10^{-10}$ ), and Apo-B (WM:  $\beta = -0.10$ ; SE = 0.01,  $P = 9.2 \times 10^{-13}$ ), and with higher Apo-A (WM:  $\beta = 0.02$ ; SE = 0.009, P = 0.007), and triglycerides (WM:  $\beta = 0.03$ ; SE = 0.009, P = 0.002). No evidence of an effect was observed for HDL (WM: P = 0.5), BMI (WM: P = 0.1), or IL-6

12

267 (IVW: P = 0.2). With respect to blood pressure outcomes evaluated, higher genetically predicted 268 TSAT was associated with higher DBP (WM:  $\beta = 0.06$ ; SE = 0.01,  $P = 1.22 \times 10^{-9}$ ), but was not 269 associated with SBP (WM: P = 0.7). Consistent effects on all CVD risk factors except for BMI 270 were observed when serum Fe and TIBC were evaluated as exposures (Tables S8-S10). While 271 genetically predicted TSAT and serum Fe were not associated with BMI, higher TIBC (indicative 272 of lower Fe status) was associated with a higher BMI (WM:  $\beta = 0.03$ ; SE = 0.009, P = 0.01). 273 Overall, the direction of effects for ferritin as the exposure were consistent with the other Fe 274 biomarkers, but weaker associations were observed due to the lower statistical power of its IVs 275 (Table S11).

276 The MR-PRESSO analyses identified possible pleiotropic outliers for all CVD risk factors 277 evaluated except for IL-6 (Tables S8-S11). For analyses of TIBC as the exposure, no change was 278 observed with respect to significance and direction of effect after implementation of the outlier 279 correction (Table S10), but few differences were observed for analyses of TSAT and serum Fe as 280 the exposures (Tables S8 and S9). The MR-PRESSO outlier-corrected estimates suggested a 281 significant association of lower genetically predicted TSAT (WM:  $\beta = -0.03$ ; SE = 0.009, P = 0.01) 282 and serum Fe (WM:  $\beta = -0.04$ ; SE = 0.01, P = 0.01) with a higher BMI, but a null effect on the 283 blood lipids and blood pressure (Tables S8 and S9). Caution should be taken when interpreting 284 these estimates as the lack of an effect may have resulted from a weak instrument and a lower 285 statistical power after the removal of SNPs.

The MR OR per 1-SD unit increase in TSAT, serum Fe, TIBC and ferritin are presented in **Table 2**. Univariate MR analyses showed evidence for a causal effect of higher Fe status on CVD outcomes, but the direction of effect differed by outcome. Higher genetically predicted Fe status, as evidenced by a higher TSAT, serum Fe, or lower TIBC, was associated with a greater risk of

13

290 CES, a lower risk of CHD, and was not associated with all-cause IS or SVS. Lower genetically 291 predicted TIBC, indicative of higher Fe status, was associated with a lower risk of LAS. Using 292 MR-PRESSO, outliers were detected for the associations of TSAT and TIBC with CHD. 293 Nonetheless, outlier-corrected estimates and P-values were in agreement with the other MR 294 methods (Table 2). Analyses for AF appeared to have significant heterogeneity (P-value for 295 Cochran's O statistic < 0.05); thus, WM and MR-PRESSO were prioritized for interpretation. 296 Consistent with the detrimental effects of higher Fe status on CES, we found greater genetically 297 predicted Fe status, as evidenced by higher TSAT and serum Fe and lower TIBC, to be associated 298 with an increased risk of AF (Table 2).

299

#### 300 Multivariate Mendelian randomization

301 We carried out MVMR utilizing selected variables meeting the prioritization criteria from 302 the univariate MR analyses. Because the power of the genetic instrument is greatly reduced when 303 conditioning on additional exposures using MVMR, we excluded ferritin from the MVMR 304 analyses given that the genetic instruments for ferritin only explain a small proportion of its 305 variance. For all MVMR models of TSAT, serum Fe or TIBC as exposures, the conditional *F*-306 statistic was > 10, demonstrating that weak instrumental bias is unlikely to be present (**Tables S12-**307 **S14**).

MVMR analyses provided evidence for a causal effect of higher Fe status on CES after conditioning on CVD risk factors, and this observation was consistent across TSAT, serum Fe and TIBC as shown in **Figure 2**. The protective effect of higher Fe status on CHD and LAS observed in the univariate MR analyses was entirely nullified after controlling for blood lipids (**Figure 3**).

14

The confounding effects of BMI on the analyses were not consistent throughout the three Fe status exposures. The protective effect of lower TIBC and higher TSAT on CHD remained significant when conditioning for BMI. However, the presumed effects serum Fe on CHD disappeared when conditioning on BMI (**Figure 3**).

Evaluation of heterogeneity using the  $Q_4$  statistic showed little to no heterogeneity in the analyses evaluating CES as the outcome (*P*-heterogeneity > 0.05) (**Table S12**). Substantial heterogeneity was noted in the MVMR analyses for CHD and LAS (*P*-heterogeneity < 0.05) (**Tables S13 and S14**). From our LDlink and PhenoScanner searches we identified two SNPs that have been shown to be associated at genome-wide significance level with coronary artery disease and one SNP with venous thromboembolism (**Table S5**). Additional sensitivity analyses excluding these three SNPs did not affect the results, thus, demonstrating robustness of findings (**Table S15**).

323

#### 324 Mediation analyses

325 We conducted mediation analyses to evaluate the indirect effect of TSAT, serum Fe and 326 TIBC on CES via selected mediators (DBP, BMI, LDL, TC, TG, Apo-B, Apo-A) using effect 327 estimates derived from univariate MR and MVMR analyses. Significant mediation of the Fe status-328 CES relationship via DBP was observed consistently across the three Fe status exposures (Table 329 3). The estimated percent of the total effect of Fe status on CES mediated by DBP was 7.1, 8.0 and 330 8.8% for serum Fe, TIBC and TSAT, respectively. The magnitude of mediation observed for BMI 331 and blood lipid fractions evaluated was substantially lower (0-2 %) and was not statistically 332 significant based on the wider 95% CI that crossed the null. Detailed calculations are shown in 333 Table S16.

15

334

## 335 **Discussion**

336 To our knowledge, this is the first study to implement MVMR to evaluate the effects of Fe 337 status on CVD outcomes while adjusting for potential confounding variables. Our findings 338 revealed a noteworthy association between higher genetically predicted Fe status and an increased 339 risk of CES that is independent of major CVD risk factors, including blood lipids, DBP, and BMI. 340 Further employing mediation analyses, we found that DBP partially mediates the effect of Fe status 341 on CES. Interestingly, while univariate MR initially suggested a protective effect of higher Fe 342 status on CHD and LAS, our comprehensive MVMR analyses factoring CVD risk factors, revealed a complete annulment of this perceived protective effect. 343

344 Our analyses using univariate two-sample MR to evaluate the effects of Fe status on CVD 345 outcomes were consistent with previous MR studies based on smaller-scale GWAS of Fe traits 346 (21-25). First, we replicated the observed protective effect of higher Fe levels on atherosclerotic 347 CVD outcomes, including CHD and LAS. We also replicated the analyses pertaining to CES 348 indicating an adverse effect of higher Fe status on this outcome. Lastly, consistent with a previous 349 MR study (50), we found an association between higher genetically predicted Fe status with an 350 increased risk of AF. This finding holds particular relevance as AF is the most significant risk 351 factor for CES (51), aligning consistently with the observed effects of Fe levels on CES.

We further evaluated the causal effects of Fe status on major CVD risk factors using univariate MR. We found, for the first time using causal inference methods, an association between higher genetically predicted Fe status and higher DBP. The lack on an association between Fe status and SBP may have resulted from a low statistical power as suggested by our power

16

356 calculations. Few studies to date have evaluated the potential effects of Fe status on blood pressure. 357 A phenome-wide association study implementing MR found higher Fe status to increase risk of hypertension at a nominal significance level (25). In agreement, observational studies have shown 358 359 that higher serum ferritin is associated with an increased risk of hypertension in adult men (52, 360 53), and serum Fe was found to be positively associated with an increased risk of hypertension 361 during pregnancy (54). We then evaluated the causal effects of Fe status on BMI and found lower 362 Fe status, as evidenced by higher TIBC, to be associated with a higher BMI. This is consistent 363 with observational studies reporting a relationship between obesity and Fe deficiency, which is 364 believed to stem from an interplay between Fe regulation and adiposity (55). With respect to blood 365 lipids, higher genetically predicted Fe status was associated with better lipid profiles as evidenced 366 by lower LDL, TC, and Apo-B and higher Apo-A concentrations. While these results are in 367 agreement with a previous MR study showing an association between genetically predicted higher 368 serum Fe and lower LDL and TC levels, and a decreased risk of hypercholesteremia and 369 hyperlipidemia (24, 56), we found evidence suggestive of substantial pleiotropy in the analyses. 370 The observed heterogeneity likely results from the significant overlap between Fe and lipid IVs as 371 evidenced by our sensitivity analyses showing a lack of an association after removal of pleiotropic 372 outliers. Lastly, genetically predicted Fe status was not associated with IL-6 in our analyses. 373 Nonetheless, future MR studies should evaluate this relationship in the opposite direction (i.e., the 374 effects of IL-6 on Fe status) as it is well-established that inflammation, particularly via IL-6, is a 375 negative regulator of Fe status (57).

Although the results from univariate MR analyses carry important implications, a major limitation is the potential bias introduced by pleiotropic effects of the genetic instruments as several Fe-associated SNPs are strongly associated with major CVD risk factors. To overcome this

17

379 limitation, we performed MVMR analyses conditioning on selected CVD risk factors. Most 380 notably, with these analyses we found that the effects of Fe status on CES were unaffected by 381 adjustment for DBP, BMI, or blood lipids (LDL, TC, TG, Apo-B, Apo-A). This provides evidence 382 in support of a causal effect of higher Fe status on CES incidence that is independent of major 383 CVD risk factors. Available observational evidence evaluating the associations between Fe status 384 and risk of stroke is inconclusive as reviewed (25). However, these contrasting observations may 385 stem from differences between IS subtypes as evidenced by our opposing results when evaluating 386 IS by subtype. This highlights the importance of evaluating IS with stratification by subtype.

387 We hypothesized that Fe's detrimental effect on CES is at least partially mediated by CVD risk factors evaluated in this study. Using mediation analyses, we identified DBP as potential 388 389 pathway through which elevated Fe levels contribute to an increased risk of CES. Accumulation 390 of excess Fe, such that it increases the labile Fe pool, results in the production of highly reactive 391 species, consequently inducing oxidative stress. It is known that oxidative stress contributes to the 392 pathogenesis of hypertension (58), a common vascular risk factor for CES. Thus, Fe-induced 393 oxidative stress may be a mechanism by which higher Fe levels influence CES development 394 directly and indirectly via its effects on blood pressure. Blood lipids did not appear to play a 395 mediating role in the relationship between Fe status and CES, suggesting that the effect of higher 396 Fe status on CES risk is unlikely to operate via the blood lipid fractions evaluated.

In contrast to the robust evidence observed for CES, the apparent protective effect of higher
Fe status on CHD and LAS was diminished after adjustment for CVD risk factors using MVMR,
suggesting a lack of a direct effect of Fe status on CHD and LAS when accounting for major CVD
risk factors. Of note, significant heterogeneity was observed in these analyses, particularly when

18

401 evaluating CHD as the outcome. Thus, more investigations are needed to characterize the complex
402 interplay between Fe, atherosclerosis, and subsequent CVD outcomes.

403 Our study has limitations that warrant attention. First, due to our reliance on summary-404 rather than individual-level data, we were unable to explore potential sex-based differences in the 405 relationships between Fe status and CVD risk factors. This is particularly relevant to Fe and CVD 406 as both Fe status markers and risk of CVD differ significantly between males and females. To our 407 knowledge, there are no sex-stratified summary-level GWAS data from either Fe status or CVD 408 that are publicly available and adequately powered to address these questions. However, it remains 409 crucial to replicate these analyses in males and females separately. Furthermore, while we selected 410 the best available outcome datasets that closely matched the population in the exposure dataset 411 and that adjusted for similar covariates, the possibility of population stratification cannot be ruled 412 out. Additionally, since our study was based in European populations, we are unable to extrapolate 413 our results to non-European populations. Evaluating this question in other populations is of 414 pressing need as risk of excess body Fe accumulation differs between populations, with individuals 415 of East Asian ancestry presenting the greatest body Fe burden (59). Another important 416 consideration is that MR methods estimate the lifetime effect of Fe status; thus, the magnitude of 417 the MR estimates may be greater in our study than what would be observed clinically. This 418 characteristic of MR holds implications for our study as Fe accumulation differs throughout life 419 stages. For instance, risk of Fe overload in females escalates post-menopause due to the cessation of menses and the effect size of elevated Fe on disease development may differ accordingly. Lastly, 420 421 all MR approaches implemented in this study assume linear associations. However, there is a 422 possibility that the effect of Fe on some of the exposures evaluated is not linear, potentially 423 masking some effects.

19

424	In conclusion, our findings underscore the significance of Fe status as a novel modifiable
425	risk factor for CES. Additionally, when controlling for CVD risk factors, the presumed protective
426	effect of higher Fe status on atherosclerotic heart disease outcomes was negated. Future studies
427	are needed to evaluate possible sex and population differences in the effects of Fe status on CVD
428	risk. Lastly, given the inherent limitations of MR methods, additional studies are needed to confirm
429	then clinical utility of Fe status in predicting risk of CES.
430	
431	
432	
433	
434	
435	
436	
437	
438	
439	
440	
441	
442	
443	
444	
445	
446	

20

447 Acknowledgements: We thank the CARDIoGRAMplusC4D, MEGASTROKE, UK Biobank
448 investigators for making their data publicly available. The MEGASTROKE project received
449 funding from sources specified at <u>http://www.megastroke.org/acknowledgments.html</u>.

450 **Author's Contributions:** AB designed and conducted the research, analyzed and interpreted the 451 data, and wrote the manuscript; AGC, EKP and KOO interpreted the data and assisted with the 452 manuscript preparation.

453 Data and Code Availability: The GWAS summary-level data are publicly available for all 454 exposures and outcomes evaluated. The exposure summary-statistic can be found directly from the 455 original GWAS publication (27). Data on coronary artery disease have been contributed by CARDIoGRAMplusC4D investigators. The UK Biobank, CARDIOGRAMplusC4D consortium, 456 457 MEGASTROKE, and IL-6 GWAS summary-level data are available in IEU OpenGWAS 458 (https://gwas.mrcieu.ac.uk/). The MR analysis code may be obtained from the corresponding 459 author upon reasonable request. 460 Funding Sources: This work was supported by the American Heart Association (23PRE1025636)

- and the NIH National Institute of Diabetes and Digestive and Kidney Diseases (R01DK122216).
- 462 The funding sources were not involved in the preparation of the manuscript.
- 463 **Disclosures:** None (AB, AGC, EKP, KOO).

# References

1. Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, et al. Criteria for Iron Deficiency in Patients With Heart Failure. J Am Coll Cardiol. 2022;79(4):341-51.

2. Fernández-Real JM, Manco M. Effects of iron overload on chronic metabolic diseases. Lancet Diabetes Endocrinol. 2014;2(6):513-26.

3. Jenkitkasemwong S, Wang CY, Coffey R, Zhang W, Chan A, Biel T, et al. SLC39A14 Is Required for the Development of Hepatocellular Iron Overload in Murine Models of Hereditary Hemochromatosis. Cell Metab. 2015;22(1):138-50.

4. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9(9):1187-94.

5. Fang X, Ardehali H, Min J, Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 2022:1-17.

6. Wu X, Li Y, Zhang S, Zhou X. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021;11(7):3052-9.

Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1(8233):1293 4.

8. Bagheri B, Shokrzadeh M, Mokhberi V, Azizi S, Khalilian A, Akbari N, et al. Association between Serum Iron and the Severity of Coronary Artery Disease. Int Cardiovasc Res J. 2013;7(3):95-8.

9. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803-11.

10. Ahluwalia N, Genoux A, Ferrieres J, Perret B, Carayol M, Drouet L, et al. Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr. 2010;140(4):812-6.

11. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997;96(10):3300-7.

12. Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord. 2009;9:34.

13. Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin is independently associated with the presence of coronary artery calcium in 12,033 men. Arterioscler Thromb Vasc Biol. 2012;32(10):2525-30.

14. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF, Jr., et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103(23):2799-804.

15. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssönen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol. 1998;148(5):445-51.

16. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion. 2002;42(9):1135-9.

17. Houschyar KS, Lüdtke R, Dobos GJ, Kalus U, Broecker-Preuss M, Rampp T, et al. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med. 2012;10:54.

18. Bozzini C, Girelli D, Tinazzi E, Olivieri O, Stranieri C, Bassi A, et al. Biochemical and genetic markers of iron status and the risk of coronary artery disease: an angiography-based study. Clin Chem. 2002;48(4):622-8.

19. Yunker LM, Parboosingh JS, Conradson HE, Faris P, Bridge PJ, Buithieu J, et al. The effect of iron status on vascular health. Vasc Med. 2006;11(2):85-91.

20. Galan P, Noisette N, Estaquio C, Czernichow S, Mennen L, Renversez JC, et al. Serum ferritin, cardiovascular risk factors and ischaemic heart diseases: a prospective analysis in the SU.VI.MAX (SUpplementation en VItamines et Minéraux AntioXydants) cohort. Public Health Nutr. 2006;9(1):70-4.

21. Gill D, Del Greco MF, Walker AP, Srai SKS, Laffan MA, Minelli C. The Effect of Iron Status on Risk of Coronary Artery Disease: A Mendelian Randomization Study-Brief Report. Arterioscler Thromb Vasc Biol. 2017;37(9):1788-92.

22. Gill D, Brewer CF, Monori G, Trégouët DA, Franceschini N, Giambartolomei C, et al. Effects of Genetically Determined Iron Status on Risk of Venous Thromboembolism and Carotid Atherosclerotic Disease: A Mendelian Randomization Study. J Am Heart Assoc. 2019;8(15):e012994.

23. Yang F, Bao Q, Wang Z, Ma M, Shen J, Ye F, et al. Sex-Specific Genetically Predicted Iron Status in relation to 12 Vascular Diseases: A Mendelian Randomization Study in the UK Biobank. Biomed Res Int. 2020;2020:6246041.

24. Gill D, Benyamin B, Moore LSP, Monori G, Zhou A, Koskeridis F, et al. Associations of genetically determined iron status across the phenome: A mendelian randomization study. PLoS Med. 2019;16(6):e1002833.

25. Gill D, Monori G, Tzoulaki I, Dehghan A. Iron Status and Risk of Stroke. Stroke. 2018;49(12):2815-21.

26. Benyamin B, Esko T, Ried JS, Radhakrishnan A, Vermeulen SH, Traglia M, et al. Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nat Commun. 2014;5:4926.

27. Moksnes MR, Graham SE, Wu KH, Hansen AF, Gagliano Taliun SA, Zhou W, et al. Genome-wide meta-analysis of iron status biomarkers and the effect of iron on all-cause mortality in HUNT. Commun Biol. 2022;5(1):591.

28. Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman Å K, Schork A, et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat Metab. 2020;2(10):1135-48.

29. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121-30.

30. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018;50(4):524-37.

31. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40(7):597-608.

32. Roselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM, et al. Multiethnic genome-wide association study for atrial fibrillation. Nat Genet. 2018;50(9):1225-33.

33. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755-64.

34. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019;4:186.

35. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-25.

36. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304-14.

37. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7.

38. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol. 2019;48(3):713-27.

39. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. Stat Med. 2021;40(25):5434-52.

40. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734-9.

41. Sanderson E. Multivariable Mendelian Randomization and Mediation. Cold Spring Harb Perspect Med. 2021;11(2).

42. Carter RC, Georgieff MK, Ennis KM, Dodge NC, Wainwright H, Meintjes EM, et al. Prenatal alcohol-related alterations in maternal, placental, neonatal, and infant iron homeostasis. Am J Clin Nutr. 2021;114(3):1107-22.

43. Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, Heron J, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36(5):465-78.

44. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693-8.

45. Lin SH, Brown DW, Machiela MJ. LDtrait: An Online Tool for Identifying Published Phenotype Associations in Linkage Disequilibrium. Cancer Res. 2020;80(16):3443-6.

46. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics. 2016;32(20):3207-9.

47. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019;35(22):4851-3.

48. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5):1497-501.

49. Deng L, Zhang H, Yu K. Power calculation for the general two-sample Mendelian randomization analysis. Genet Epidemiol. 2020;44(3):290-9.

50. Wang T, Cheng J, Wang Y. Genetic support of a causal relationship between iron status and atrial fibrillation: a Mendelian randomization study. Genes Nutr. 2022;17(1):8.

51. Khurshid S, Trinquart L, Weng LC, Hulme OL, Guan W, Ko D, et al. Atrial Fibrillation Risk and Discrimination of Cardioembolic From Noncardioembolic Stroke. Stroke. 2020;51(5):1396-403.

52. Kim MK, Baek KH, Song KH, Kang MI, Choi JH, Bae JC, et al. Increased serum ferritin predicts the development of hypertension among middle-aged men. Am J Hypertens. 2012;25(4):492-7.

53. Lee DH, Kang SK, Choi WJ, Kwak KM, Kang D, Lee SH, et al. Association between serum ferritin and hypertension according to the working type in Korean men: the fifth Korean National Health and nutrition examination survey 2010-2012. Ann Occup Environ Med. 2018;30:40.

54. Song QY, Luo WP, Zhang CX. High serum iron level is associated with an increased risk of hypertensive disorders during pregnancy: a meta-analysis of observational studies. Nutr Res. 2015;35(12):1060-9.

55. Hilton C, Sabaratnam R, Drakesmith H, Karpe F. Iron, glucose and fat metabolism and obesity: an intertwined relationship. Int J Obes (Lond). 2023;47(7):554-63.

56. Zhou J, Liu C, Francis M, Sun Y, Ryu MS, Grider A, et al. The Causal Effects of Blood Iron and Copper on Lipid Metabolism Diseases: Evidence from Phenome-Wide Mendelian Randomization Study. Nutrients. 2020;12(10).

57. Ganz T, Nemeth E. Hypoferremia of inflammation: Innate host defense against infections. Blood Cells Mol Dis. 2024;104:102777.

58. Griendling KK, Camargo LL, Rios FJ, Alves-Lopes R, Montezano AC, Touyz RM. Oxidative Stress and Hypertension. Circ Res. 2021;128(7):993-1020.

59. Kang W, Barad A, Clark AG, Wang Y, Lin X, Gu Z, et al. Ethnic Differences in Iron Status. Adv Nutr. 2021;12(5):1838-53.

26

# Table 1. Summary of exposure and outcome genome-wide association studies (GWAS)

datasets.

	Data Source	Source ID	Consortium	Variable type	Sample Size/ Cases/controls	Population	Sex	PMID	Year
Iron statu	15								
TSAT	NTNU Open Research Data	10.18710/S9T JEL	HUNT, MGI, deCODE, INTERVAL	Continuous	198,516	EUR	M/F	35710628	2022
SI	NTNU Open Research Data	10.18710/S9T JEL	HUNT, MGI, deCODE, INTERVAL, SardiNIA	Continuous	236,612	EUR	M/F	35710628	2022
TIBC	NTNU Open Research Data	0.18710/S9TJ EL	HUNT, MGI, deCODE, INTERVAL, SardiNIA	Continuous	208,422	EUR	M/F	35710628	2022
Ferritin	NTNU Open Research Data o	10.18710/S9T JEL	HUNT, MGI, deCODE, INTERVAL, DBDS	Continuous	257,953	EUR	M/F	35710628	2022
Cardiova	scular Disease								
CHD	IEU OpenGWAS	ieu-a-7	CARDIoGRAM- plusCD4	Binary	60,801 / 123,504	Mixed (76% EUR)	M/F	26343387	2015
CES	IEU OpenGWAS	ebi-a- GCST006910	MEGASTROKE	Binary	7,193 / 406,111	EUR	M/F	29531354	2018
LAS	IEU OpenGWAS	ebi-a- GCST006907	MEGASTROKE	Binary	4,373 / 406,111	EUR	M/F	29531354	2018
SVS	IEU OpenGWAS	ebi-a- GCST006909	MEGASTROKE	Binary	5,386 / 406111	EUR	M/F	29531354	2018
IS	IEU OpenGWAS	ebi-a- GCST006908	MEGASTROKE	Binary	34,217/ 406,111	EUR	M/F	29531354	2018
AF	IEU OpenGWAS	ebi-a- GCST006061	AFGen, BroadAF, and UKBB	Binary	55,114/ 482,295	EUR	M/F	29892015	2018
Blood lipi	ids								
TG	Neale Lab (R2)	30870_irnt	UKBB	Continuous	343,992	EUR	M/F	NA	2018
TC	Neale Lab (R2)	30690_irnt	UKBB	Continuous	344,278	EUR	M/F	NA	2018
LDL	Neale Lab (R2)	30780_irnt	UKBB	Continuous	343,621	EUR	M/F	NA	2018
HDL	Neale Lab (R2)	30760_irnt	UKBB	Continuous	315,133	EUR	M/F	NA	2018
Apo B	Neale Lab (R2)	30640_irnt	UKBB	Continuous	342,590	EUR	M/F	NA	2018
Apo A	Neale Lab (R2)	30630_irnt	UKBB	Continuous	313,387	EUR	M/F	NA	2018
Blood Pre	essure								
DBP	Neale Lab (R2)	4079_irnt	UKBB	Continuous	340,162	EUR	M/F	NA	NA
SBP	Neale Lab (R2)	4080_irnt	UKBB	Continuous	340,159	EUR	M/F	NA	NA

27

Anthropometric Measure											
BMI	Neale Lab (R2)	21001_irnt	UKBB	Continuous	359,983	EUR	M/F	NA	NA		
Inflamma	Inflammatory Marker										
IL-6	IEU OpenGWAS	ebi-a- GCST900120 05	11 EUR cohorts	Continuous	21,758	EUR	M/F	33067605	2020		

AF, atrial fibrillation; Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI, body mass index;

CARDIoGRAMplusC4D, Coronary ARtery DIsease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics; CES, cardioembolic ischemic stroke; CHD, coronary heart disease; DBDS, Danish Blood Donor Study; DBP, diastolic blood pressure; EUR, European; Fe, iron; HDL, high density lipoprotein cholesterol; HUNT, Trøndelag Health Study; IL-6, interleukin-6; IS, ischemic stroke (all-types); LAS, large artery atherosclerotic ischemic stroke; LDL, low density lipoprotein cholesterol; M/F, males/females; MGI, Michigan Genomics Initiative; SBP, systolic blood pressure; SVS, small vessel ischemic stroke; TC, total cholesterol; TG, triglycerides; TIBC, total iron binding capacity; TSAT, transferrin saturatiob; UKBB, UK Biobank

28

### Table 2. Univariate two-sample Mendelian randomization analyses evaluating the

## associations of genetically predicted iron status and cardiovascular disease outcomes.

Outcome	Exposure	MR method	N SNPs	OR [95 % CI]	<i>P</i> -effect	<i>P</i> -pleiotropy*
		IVW	15	0.92 [0.83, 1.03]	0.17	0.0003
	теат	MR Egger	15	0.88 [0.77, 1.02]	0.11	0.33
	ISAI	WM	15	0.91 [0.84, 0.99]	0.02	-
		MR-PRESSO	14	0.91 [0.85, 0.99]	0.04	-
		IVW	12	0.89 [0.81, 0.98]	0.02	0.12
	Serum Iron	MR Egger	12	0.87 [0.75, 1.00]	0.07	0.56
		WM	12	0.89 [0.82, 0.98]	0.02	-
CHD		IVW	15	1.13 [1.03, 1.24]	0.01	0.23
	TIDC	MR Egger	15	1.08 [0.96, 1.20]	0.22	0.14
	ПВС	WM	15	1.10 [1.00, 1.21]	0.05	-
		MR-PRESSO	14	1.13 [1.03, 1.24]	0.03	-
		IVW	35	0.92 [0.80, 1.05]	0.23	0.04
	F	MR Egger	35	0.79 [0.61, 1.02]	0.07	0.17
	rerriun	WM	35	0.84 [0.71, 1.00]	0.05	-
		MR-PRESSO	33	0.90 [0.79, 1.02]	0.11	-
		IVW	14	1.03 [0.93, 1.13]	0.63	0.003
	TSAT	MR Egger	14	1.04 [0.92, 1.18]	0.56	0.71
	ISAI	WM	14	1.04 [0.96, 1.11]	0.35	-
IS		MR-PRESSO	12	1.02 [0.97, 1.08]	0.45	-
		IVW	12	1.04 [0.91, 1.18]	0.60	0.002
	Serum Iron	MR Egger	12	1.03 [0.86, 1.25]	0.74	0.96
		WM	12	1.03 [0.94, 1.14]	0.49	-

29

		MR-PRESSO	11	1.02 [0.93, 1.13]	0.64	-
		IVW	14	0.96 [0.89, 1.03]	0.25	0.63
	TIBC	MR Egger	14	0.96 [0.88, 1.05]	0.39	0.98
		WM	14	0.95 [0.88, 1.04]	0.26	-
		IVW	34	1.01 [0.88, 1.16]	0.85	0.16
	Ferritin	MR Egger	34	1.01 [0.77, 1.33]	0.95	0.97
		WM	34	1.06 [0.87, 1.28]	0.57	-
		IVW	14	1.17 [1.03, 1.33]	0.02	0.36
	TSAT	MR Egger	14	1.12 [0.95, 1.32]	0.19	0.42
		WM	14	1.14 [0.99, 1.31]	0.07	-
		IVW	12	1.21 [1.02, 1.44]	0.03	0.23
	Serum Iron	MR Egger	12	1.13 [0.89, 1.45]	0.34	0.44
CFS		WM	12	1.17 [0.97, 1.41]	0.09	-
CES		IVW	14	0.81 [0.69, 0.94]	0.006	0.48
	TIBC	MR Egger	14	0.84 [0.70, 1.01]	0.09	0.43
		WM	14	0.83 [0.70, 0.98]	0.03	-
		IVW	34	1.05 [0.79, 1.40]	0.72	0.04
	Ferritin	MR Egger	34	1.47 [0.84, 2.57]	0.18	0.18
		WM	34	1.38 [0.97, 1.97]	0.08	-
		IVW	14	1.03 [0.85, 1.24]	0.77	0.06
	TSAT	MR Egger	14	1.15 [0.92, 1.43]	0.25	0.13
		WM	14	1.10 [0.92, 1.31]	0.30	-
CVC		IVW	12	1.01 [0.78, 1.32]	0.92	0.02
579	Serum Iron	MR Egger	12	1.18 [0.84, 1.66]	0.37	0.23
		WM	12	1.03 [0.81, 1.31]	0.80	-
		IVW	14	0.88 [0.73, 1.05]	0.15	0.38
	TIRC	MR Egger	14	0.83 [0.67, 1.03]	0.12	0.40

30

	0.12	-
IVW 34 1.05 [0.80, 1.36]	0.75	0.66
Ferritin         MR Egger         34         1.08 [0.62, 1.87]	0.79	0.89
WM 34 1.18 [0.80, 1.73]	0.41	-
IVW 14 0.86 [0.67, 1.10]	0.22	0.006
MR Egger 14 0.86 [0.62, 1.18]	0.36	0.99
WM 14 0.84 [0.70, 1.00]	0.05	-
MR-PRESSO 13 0.87 [0.70, 1.08]	0.23	-
IVW 12 0.82 [0.61, 1.12]	0.21	0.009
<b>Serum Iron</b> MR Egger 12 0.86 [0.55, 1.33]	0.51	0.79
LAS WM 12 0.82 [0.65, 1.04]	0.10	-
IVW 14 1.23 [1.07, 1.40]	0.003	0.96
<b>TIBC</b> MR Egger 14 1.16 [0.91, 1.48]	0.24	0.45
WM 14 1.19 [0.95, 1.50]	0.12	-
IVW 34 0.83 [0.60, 1.16]	0.29	0.20
Ferritin         MR Egger         34         0.74 [0.38, 1.46]	0.39	0.70
WM 34 0.75 [0.48, 1.18]	0.21	-
IVW 11 1.07 [0.92, 1.24]	0.37	2.85x10 <sup>-17</sup>
MR Egger 11 1.00 [0.83, 1.19]	0.96	0.23
WM 11 1.07 [1.00, 1.13]	0.04	-
MR-PRESSO 8 1.09 [1.01, 1.17]	0.047	-
IVW 11 1.09 [0.90, 1.31]	0.39	1.46x10 <sup>-17</sup>
AF Serum Iron MR Egger 11 1.00 [0.75, 1.21]	0.72	0.16
WM 11 1.05 [0.96, 1.15]	0.30	-
MR-PRESSO 8 1.14 [1.02, 1.27]	0.046	-
MR-PRESSO 8 1.14 [1.02, 1.27] IVW 13 0.92 [0.85, 1.00]	0.046	- 0.01

medRxiv preprint doi: http (which was not certi	os://doi.org/10.110 fied by peer revi lt is m	01/2024.02.05.24302 ew) is the author/fur ade available under	2373; this v ider, who h a CC-BY-N	ersion posted February 6, as granted medRxiv a lice IC-ND 4.0 International lic	2024. The cop nse to display ense .	byright holder for this p the preprint in perpet	preprint uity.
						3	1
		WM	13	0.93 [0.87, 0.99]	0.02	-	
-		IVW	33	1.00 [0.88, 1.13]	0.99	0.0005	-
	Ferritin	MR Egger	33	1.08 [0.84, 1.40]	0.54	0.48	
		WM	33	1.01 [0.88, 1.16]	0.90	-	

\**P*-pleiotropy value for IVW method represents the Cochran's *Q* test and for the MR-Egger method represents the Egger-intercept test.

MR-PRESSO outlier-corrected estimates are presented when outliers were detected.

AF, atrial fibrillation; CES, cardioembolic ischemic stroke; CHD, coronary heart disease; IS, ischemic stroke (all-cause); IVW, inverse-variance weighted method under multiplicative random-effects; LAS, large artery atherosclerotic ischemic stroke; MR-PRESSO, Mendelian randomization pleiotropy residual sum and outlier test; SVS, small vessel ischemic stroke; TIBC, total iron binding capacity; TSAT, transferrin saturation; WM, weighted median.

32

# Table 3. Indirect effects reported as log odds ratio of iron status on cardioembolic stroke via

selected	mediators.

$\mathbf{E} \times \mathbf{M} \times \mathbf{O}$	Indinest offerst	CE	050/ CI	% of total effect
$E \rightarrow M \rightarrow 0$	indirect effect	SE	95% CI	mediated
TSAT-DBP-CES	0.014	0.006	0.004, 0.028	8.8
TSAT-BMI-CES	-0.002	0.002	-0.006, 0.002	1.3
TSAT-LDL-CES	0.001	0.008	-0.014, 0.016	0.6
TSAT-TC-CES	0.001	0.007	-0.013, 0.015	0.6
TSAT-TG-CES	0	0.002	-0.003, 0.004	0
TSAT-ApoB-CES	0.001	0.006	-0.011, 0.013	0.6
TSAT-ApoA-CES	-0.002	0.002	-0.006, 0	1.3
SI-DBP-CES	0.014	0.007	0.003, 0.029	7.1
SI-BMI-CES	0	0.002	-0.006, 0.004	0
SI-LDL-CES	0.001	0.008	-0.018, 0.016	0.5
SI-TC-CES	0.001	0.008	-0.015, 0.018	0.5
SI-TG-CES	0	0.002	-0.004, 0.004	0
SI-ApoB-CES	0.002	0.007	-0.013, 0.016	1.0
SI-ApoA-CES	-0.003	0.002	-0.009, 0	1.5
TIBC-DBP-CES	-0.015	0.006	-0.028, -0.005	8.0
TIBC-BMI-CES	0.003	0.002	0.000, 0.007	1.6
TIBC-LDL-CES	0	0.008	-0.015, 0.015	0
TIBC-TC-CES	-0.001	0.007	-0.015, 0.013	0.5
TIBC-TG-CES	0	0.001	-0.003, 0.002	0
TIBC-ApoB-CES	0	0.007	-0.013, 0.013	0
TIBC-ApoA-CES	0.002	0.001	0, 0.005	1.1

The indirect effect is reported as the log odds ratio.

33

The standard error (SE) and 95% CI for the for the indirect effect was calculated using the delta method. The SE was calculated as:  $\sqrt{EM \beta^2 x MO SE^2 + MO \beta^2 x EM SE^2}$ .

The percent of the total effect mediated was calculated as the estimated indirect effect divided by the total effect from univariate MR x 100.

Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI, body mass index; CES, cardioembolic ischemic stroke; DBP, diastolic blood pressure;  $E \rightarrow M \rightarrow O$ , exposure  $\rightarrow$  mediator  $\rightarrow$  outcome; LDL, low density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; TIBC; total iron binding capacity; TSAT, transferrin saturation; SI, serum iron.

#### 34

#### Figure 1. Study design and workflow.



CVD, cardiovascular disease; Fe, iron; IVW, inverse variance weighted; MR, Mendelian Randomization; MR-PRESSO, Mendelian randomization pleiotropy residual sum and outlier test; MVMR, multivariate mendelian randomization.

35

### Figure 2. Associations between genetically predicted iron status and cardioembolic

ischemic stroke using univariate and multivariate Mendelian randomization.



MR estimates presented as odds ratio (OR) and 95% confidence intervals (CI) per 1-SD unit increase in the Fe exposure.

Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI, body mass index; CES, cardioembolic ischemic stroke; DBP, diastolic blood pressure; LDL, low density lipoprotein cholesterol; MVMR, multivariate Mendelian randomization; TC, total cholesterol; TG, triglycerides; UVMR, univariate Mendelian randomization.

36

Figure 3. Associations between genetically predicted iron status and atherosclerotic cardiovascular disease outcomes using univariate and multivariate Mendelian randomization.



MR estimates presented as odds ratio (OR) and 95% confidence intervals (CI) per 1-SD unit increase in the Fe exposure.

Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI, body mass index; DBP, diastolic blood pressure; CHD, coronary heart disease; LAS, large artery atherosclerotic ischemic stroke; LDL, low density lipoprotein cholesterol; MVMR, multivariate Mendelian randomization; TC, total cholesterol; TG, triglycerides; UVMR, univariate Mendelian randomization.